Conjugation of Emtansine Onto Trastuzumab Promotes Aggregation of the Antibody-Drug Conjugate by Reducing Repulsive Electrostatic Interactions and Increasing Hydrophobic Interactions.

[1]  J. Carpenter,et al.  Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates. , 2018, Journal of pharmaceutical sciences.

[2]  H. Gieseler,et al.  Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates. , 2018, Molecular pharmaceutics.

[3]  Brittney J. Mills,et al.  Effects of localized interactions and surface properties on stability of protein‐based therapeutics , 2018, The Journal of pharmacy and pharmacology.

[4]  Z. Sauna,et al.  Immunogenicity assessment during the development of protein therapeutics , 2018, The Journal of pharmacy and pharmacology.

[5]  D. K. Schwartz,et al.  Protein–protein interactions controlling interfacial aggregation of rhIL‐1ra are not described by simple colloid models , 2018, Protein science : a publication of the Protein Society.

[6]  Athena W Wong,et al.  High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers. , 2018, Bioconjugate chemistry.

[7]  John F. Carpenter,et al.  Some Lessons Learned From a Comparison Between Sedimentation Velocity Analytical Ultracentrifugation and Size Exclusion Chromatography to Characterize and Quantify Protein Aggregates. , 2017, Journal of pharmaceutical sciences.

[8]  C. Dumontet,et al.  Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.

[9]  Weibin Chen,et al.  In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate , 2016, mAbs.

[10]  D. Metcalfe,et al.  Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events. , 2016, Journal of pharmaceutical sciences.

[11]  Sandeep Kumar,et al.  Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation. , 2016, Bioconjugate chemistry.

[12]  W. Jiskoot,et al.  Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics , 2015, Pharmaceutical Research.

[13]  S. Owen,et al.  Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry , 2015, The AAPS Journal.

[14]  Yan Chen,et al.  Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. , 2014, Bioconjugate chemistry.

[15]  Kelly A. Schwarz,et al.  Auristatin antibody drug conjugate physical instability and the role of drug payload. , 2014, Bioconjugate chemistry.

[16]  Paul Polakis,et al.  Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.

[17]  Heather Flores,et al.  Investigation into temperature-induced aggregation of an antibody drug conjugate. , 2013, Bioconjugate chemistry.

[18]  Theodore W Randolph,et al.  The effects of excipients on protein aggregation during agitation: an interfacial shear rheology study. , 2013, Journal of pharmaceutical sciences.

[19]  S. Langille,et al.  Particulate Matter in Injectable Drug Products , 2013, PDA Journal of Pharmaceutical Science and Technology.

[20]  Theodore W Randolph,et al.  Excipient effects on humanized monoclonal antibody interactions with silicone oil emulsions. , 2012, Journal of pharmaceutical sciences.

[21]  Deborah S. Goldberg,et al.  Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. , 2011, Journal of pharmaceutical sciences.

[22]  Yatin R. Gokarn,et al.  Analytical methods for physicochemical characterization of antibody drug conjugates , 2011, mAbs.

[23]  Theodore W Randolph,et al.  Aggregation of recombinant human botulinum protein antigen serotype C in varying solution conditions: implications of conformational stability for aggregation kinetics. , 2011, Journal of pharmaceutical sciences.

[24]  Theodore W Randolph,et al.  Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. , 2011, Journal of pharmaceutical sciences.

[25]  Aditya A Wakankar,et al.  Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. , 2010, Bioconjugate chemistry.

[26]  D. Verthelyi,et al.  Regulatory Perspective on Aggregates as a Product Quality Attribute , 2010 .

[27]  Theodore W Randolph,et al.  Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability. , 2009, Biochemistry.

[28]  Theodore W Randolph,et al.  Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. , 2009, Journal of pharmaceutical sciences.

[29]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[30]  D. Wuttke,et al.  High concentration formulations of recombinant human interleukin-1 receptor antagonist: I. Physical characterization. , 2008, Journal of pharmaceutical sciences.

[31]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[32]  D. Katayama,et al.  Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. , 2006, Biochemistry.

[33]  John M Lambert,et al.  Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry , 2005, Protein science : a publication of the Protein Society.

[34]  M. Meinders,et al.  Quantitative description of the relation between protein net charge and protein adsorption to air-water interfaces. , 2005, The journal of physical chemistry. B.

[35]  Theodore W Randolph,et al.  Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony‐stimulating factor , 2003, Protein science : a publication of the Protein Society.

[36]  John F. Carpenter,et al.  Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.

[37]  Magdassi,et al.  Chemically Modified Human Immunoglobulin G: Hydrophobicity and Surface Activity at Air/Solution Interface. , 1999, Journal of colloid and interface science.

[38]  J L Cleland,et al.  Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. , 1998, Journal of pharmaceutical sciences.

[39]  M. Manning,et al.  Aggregation of recombinant human interferon gamma: kinetics and structural transitions. , 1998, Journal of pharmaceutical sciences.

[40]  Magdassi,et al.  Adsorption of Hydrophobized Glucose Oxidase at Solution/Air Interface , 1997, Journal of colloid and interface science.

[41]  P. Wyatt.  Light scattering and the absolute characterization of macromolecules , 1993 .

[42]  G. Narsimhan,et al.  Kinetics of Adsorption of Globular Proteins at an Air‐Water Interface , 1992, Biotechnology progress.

[43]  R. Chari,et al.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[44]  T. Dobashi,et al.  Chapter 7 – Light Scattering , 2000 .